Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038690 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| Hydrochloric Acid SCHEMBL3930855 | 0.98 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| Acetic Acid SCHEMBL5795551 | 0.93 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL3709825 | 0.85 | NQO1 (0.40) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL6328367 | 0.83 | SLC6A2 (0.51) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL4618228 | 0.81 | SLC6A2 (0.45) | SLC6A4SLC6A3SLC6A2LMNACYP1A2 | |
| SCHEMBL4625904 | 0.80 | MME (0.36) | SLC6A4SLC6A3SLC6A2HTR2A | |
| SCHEMBL4967524 | 0.79 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL8040630 | 0.79 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL8038699 | 0.79 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100520-A1 | A PROCESS FOR PREPARATION OF PHENETHYLAMINE DERIVATIVE | HIKAL LIMITED (IN) | 2010-09-10 | — | — | WO | claimed |
| WO-2010046808-A2 | A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | claimed |
| EP-2121574-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES | Pharmathen S.A. (GR) | 2009-11-25 | — | — | EP | claimed |
| EP-2061750-A2 | IMPROVED PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | Medichem, S.A. (ES) | 2009-05-27 | — | — | EP | claimed |
| EP-2043999-A2 | A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE | Aarti Healthcare Limited (IN) | 2009-04-08 | — | — | EP | claimed |
| WO-2008083708-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES | PHARMATHEN S.A. (GR) | 2008-07-17 | — | — | WO | claimed |
| WO-2008015584-A2 | IMPROVED PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | MEDICHEM, S.A. (US) | 2008-02-07 | — | — | WO | claimed |
| EP-1824815-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-29 | — | — | EP | claimed |
| WO-2007069277-A2 | A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE | AARTI HEALTHCARE LIMITED (IN) | 2007-06-21 | — | — | WO | claimed |
| WO-2007047972-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-26 | — | — | WO | claimed |
| WO-2006067808-A1 | AN IMPROVED PROCESS FOR PRODUCTION OF INTERMEDIATE OF ANTIDEPRESSANT AGENT | CALYX CHEMICALS & PHARMACEUTICALS PRIVATE LIMITED (IN) | 2006-06-29 | — | — | WO | claimed |
| EP-1490325-A1 | MANUFACTURE OF PHENYL ETHYLAMINE COMPOUNDS, IN PARTICULAR VENLAFAXINE | Nicholas Piramal India Limited (IN) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080560-A1 | MANUFACTURE OF PHENYL ETHYLAMINE COMPOUNDS, IN PARTICULAR VENLAFAXINE | GLOBAL BULK DRUGS & FINE CHEMICALS PVT. LTD. (IN) | 2003-10-02 | — | — | WO | claimed |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SUNOVION PHARMACEUTICALS INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-9072700-B2 | Methods of using derivatives of (−)-venlafaxine | SUNOVION PHARMACEUTICALS INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140121283-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | SUNOVION PHARMACEUTICALS INC. (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2000059851-A1 | DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SEPRACOR INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000032556-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SEPRACOR INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000032555-A1 | DERIVATIVES OF (+)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SEPRACOR INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | COMT, MAOA, MAOB | SLC6A4 11/4885SLC6A3 5/4885SLC6A2 4/4885 |
| US-20140121283-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | COMT, MAOA, MAOB | SLC6A4 10/4885SLC6A3 5/4885SLC6A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.